Brian Bourdot and Analyst - Free people check

(1 - 37 from 49

)

Frankfurt - K+S-Aktienanalyse von Aktienanalyst Brian Bourdot von der...

www.ad-hoc-news.de

K+S-Aktie zu hoch bewertet - Deutsche Bank rät zum Verkauf! Aktienanalyse.

Amylin shares swoon as diabetes rivals emerge - Reuters

www.reuters.com

Deutsche Bank analyst Brian Bourdot said the positive liraglutide results were as expected, given the drug had appeared consistently more ...

Europe health companies produce mixed reports - MarketWatch

www.marketwatch.com

... given different consensus measures indicated market expectations for 10% to 12% operating profit growth," wrote Brian Bourdot, a Deutsche Bank analyst,

Bayer-Aktie: Spezial- und Biotech-Produkte stehen zunehmend im Fokus

www.finanznachrichten.de

London - Mark Purcell, Michael Leuchten und Brian Bourdot, Analysten von Barclays, stufen die Aktie von Bayer (ISIN DE000BAY WKN BAY001) unverändert mit "equal

Data.com: Brian Bourdot

Job: Research Analyst; City: New York; Company: Barclays Capital Inc.

LinkedIn: Brian Bourdot | LinkedIn

View Brian Bourdot’s professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Brian Bourdot ...

Analysten-Einstufungen vom BÖRSE ONLINE

www.boerse-online.de

#TEXT#

America's Medical Industry: The Good, the Bad, and the Deadly

books.google.co.uk

Brian Bourdot, an analyst at the investment bank Barclays Capital, called the settlement an important step but also noted that GlaxoSmithKline “remains involved ...

'how well do gsk balance demands for shareholder value with ...

www.homeworkmarket.com

Strategy seems sensible but delivery will take time Brian Bourdot Research Analyst (+44) Michael Leuchten Research ...

Patently obvious Glaxo's cure is hidden in diverse portfolio;...

www.thefreelibrary.com

Deutsche Bank analyst Brian Bourdot said in a note to investors. "It seems sensible, but investors are paying for big pharma revenue growth and any impact on ...

report - PharmaLivewww.pharmalive.com › uploads › › MedAdNews-Octo

www.pharmalive.com

“It's a bit of a surprise that they changed course mid- year, but a new chief executive likes to take control and see what the options are,” Brian Bourdot, an analyst.

Novo Nordisk A/S., the world's biggest insulin maker, said...

www.thefreelibrary.com

Such tests could delay approval for 2 to 3 years, analysts led by Brian Bourdot said. "We expect the focus for investors will now shift to the pending FDA update ...

Big Pharma Paying Out Huge Fraud Settlements | Dr. Steve Best

drstevebest.wordpress.com

To wit, a note to investors from Barclays Capital analyst Brian Bourdot earlier this month in the wake of the record-breaking Glaxo deal: “We ...

AZ outlook from the street | Page 14 | Cafepharma ...www.cafepharma.com › ... › Pharma/Biotech Companies › AstraZeneca

www.cafepharma.com

The decision to stop repurchasing shares gives the drugmaker more flexibility to undertake a big acquisition, said Brian Bourdot, an analyst at ...

Glaxo Settles Cases With U.S. for $3 Billion – but still no ...

seroxatsecrets.wordpress.com

Brian Bourdot, an analyst at the investment bank Barclays Capital, called the settlement an important step but also noted that GlaxoSmithKline ...

July | | Old CardioBrief

cardiobrief.wordpress.com

Barclays Capital analyst Brian Bourdot wrote that "the documents read more favorably in support of approval than we had … Continue reading ...

Brian Bourdot | LinkedIn

www.linkedin.com

View Brian Bourdot's professional profile on LinkedIn. Brian Bourdot Equity Analyst at Deutsche Bank Location St Albans, United Kingdom Industry Investment Banking

Biogen Idec-Aktie: Neues Kursziel (Barclays) | Analysen |...

www.aktiencheck.de

London (www.aktiencheck.de) - Matthew Taylor, C. Anthony Butler, Mark Purcell und Brian Bourdot, Analysten von Barclays, stufen die Aktie von Biogen Idec unverändert

DRUGS & PHARMACROPS: Novo Nordisk profits from high GE insulinprices...

www.gene.ch

"Hedging gains are providing some offset to currency headwinds," said Brian Bourdot, an analyst at UBS in London. Rebates, Taxes In the U.S.,

"son of Advair". | COPD in Canada & The World

philns.proboards.com

... that onerous new development requirements could be placed on new LABAs," Deutsche Bank analyst Brian Bourdot said in a research note.

Big Pharma Paying Out Huge Settlements In Marketing Cases | Fox...

www.foxbusiness.com

· Big Pharma Paying Out Huge Settlements In ... a note to investors from Barclays Capital analyst Brian Bourdot earlier this month in the ...

Interim UCB S.A Earnings Conference Call Transcript - Transcript...

www.alacrastore.com

...Brian Bourdot Barclays Capital - Analyst Peter Verdult Morgan Stanley - Analyst Richard Vosser JPMorgan - Analyst Andy Cosen Redburn Partners - Analyst Jan...

K+S-Aktie zu hoch bewertet - Deutsche Bank rät zum Verkauf!...

www.aktiencheck.de

Frankfurt (www.aktiencheck.de) - K+S-Aktienanalyse von Aktienanalyst Brian Bourdot von der Deutsche Bank: Brian Bourdot, Aktienanalyst der Deutsche Bank ...

Mixed reviews for Brilinta prior to Wednesday’s FDA panel

www.cardiobrief.org

Mixed reviews for Brilinta prior to ... Barclays Capital analyst Brian Bourdot wrote that “the documents read more favorably in support of ...

New chief halts AZ buybacks to review strategy | FiercePharma

www.fiercepharma.com

CEO Pascal Soriot may want cash for deals, analysts say

AstraZeneca: Kursziel gesenkt « Aktienjournal.de

www.aktienjournal.de

London (www.aktiencheck.de) - Die Analysten von Barclays, Mark Purcell, Brian Bourdot, Michael Leuchten und Olivia Capra, bestätigen das equal ...

AstraZeneca Management Discusses Q Results – Earnings Call...

www.nasdaq.com

Jonathan Hunt – IR. Simon Lowth – CFO. Ed Pierson – Global Early Development Project Manager. Analysts. Brian Bourdot – Barclays Capital.

DRUGS: Novo Nordisk growth threatened by new Lilly drug

www.gene.ch

... so liraglutide probably needs to show more benefits than the weekly Byetta to gain customers, said Brian Bourdot, analyst at Deutsche Bank.

Brain Tumour Survivor • View topic - Drug company scrutinised over...

www.btsurvivor.com

To wit, a note to investors from Barclays Capital analyst Brian Bourdot earlier this month in the wake of the record-breaking Glaxo deal: “We ...

Biogen Idec: Neues Kursziel « Aktienjournal.de

www.aktienjournal.de

London (www.aktiencheck.de) - Matthew Taylor, C. Anthony Butler, Mark Purcell und Brian Bourdot, Analysten von Barclays, stufen die Aktie von Biogen Idec ...

Nielegalny marketing GlaxoSmithKline - Prawda2

prawda2.info

Brian Bourdot, an analyst at the investment bank Barclays Capital, called the settlement an important step but also noted that GlaxoSmithKline ...

Novo Nordisk-Aktie: “underweight” | Aktienjournal.de

www.aktienjournal.de

London (www.aktiencheck.de) - Brian Bourdot, Mark Purcell, Michael Leuchten, Edward J. Dulac III und C. Anthony Butler, Analysten von Barclays Capital, ...

UCB says net profit fell 59 per cent - The Economic Times

m.economictimes.com

Results are in line with expectations, said Deutsche Bank analyst Brian Bourdot. ``The dividend was a bit higher than we thought,'' he said. UCB proposed a ...

US FDA calls for new safety controls on long-acting asthma ...

www.thepharmaletter.com

... lung disease GSK is working on with the USA's Theravance, according to Barclays Capital analysts Mark Purcell and Brian Bourdot, who said ...

Q U C B SA Half-year Results Conference Call Transcript -...

www.alacrastore.com

...Richard Parkus Deutsche Bank - Analyst Nicholas Groen Exane BNP Paribas - Analyst Peter Welford Jefferies & Company - Analyst Richard Vosser JPMorgan -...

novo | NPinvestor

npinvestor.dk

Diabetics would prefer fewer shots so liraglutide probably needs to show more benefits than the weekly Byetta to gain customers, said Brian Bourdot, analyst at ...

All web results to the name "Brian Bourdot"

Related search requests for Brian Bourdot

Mike Frith

People
Forename "Brian" (70775)
Name "Bourdot" (13)

sorted by relevance / date

Advanced Search

Search name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Brian Bourdot and Analyst Free People Check